A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease

NCT05970640 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-alcoholic Fatty Liver Disease
Obesity

Interventions

DRUG: BI 3006337
DRUG: Placebo matching BI 3006337

Sponsor

Boehringer Ingelheim